Analysts expect Innate Pharma SA to report revenue of 59.55 M for 2026, against a range of 56.14 M to 62.95 M. The most recent reported year, 2025, came in at 10.39 M, a 41.4% miss against the 17.74 M consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 27.19 M | 62.81 M | 66.95 M | 21.73 M | 10.39 M | - | - | ||
| High Estimate | 56.79 M | 82.07 M | 59.60 M | 41.89 M | 18.91 M | 62.95 M | 83.95 M | ||
| Low Estimate | 52.54 M | 67.16 M | 55.30 M | 36.75 M | 16.57 M | 56.14 M | 75.80 M | ||
| Consensus Estimate | 54.66 M | 74.61 M | 57.45 M | 39.32 M | 17.74 M | 59.55 M | 79.87 M |
Analysts expect Innate Pharma SA to report earnings per share of -0.18 for 2026, against a range of -0.19 to -0.17. The most recent reported year, 2025, came in at -0.63, a 6.0% beat against the -0.67 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.63 | -0.79 | -0.10 | -0.66 | -0.63 | - | - | ||
| High Estimate | -0.57 | -0.31 | -0.58 | -0.33 | -0.64 | -0.17 | -0.15 | ||
| Low Estimate | -0.67 | -0.35 | -0.68 | -0.37 | -0.70 | -0.19 | -0.17 | ||
| Consensus Estimate | -0.62 | -0.33 | -0.63 | -0.35 | -0.67 | -0.18 | -0.16 |
Pull Wall Street consensus for Innate Pharma SA (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=IPHA&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "IPHA", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=IPHA&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();